Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trialResearch in context

Authors: Joon Young Song, Won Suk Choi, Jung Yeon Heo, Eun Jin Kim, Jin Soo Lee, Dong Sik Jung, Shin-Woo Kim, Kyung-Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Byung Wook Yoo, In-Jin Jang, Maria Z. Capeding, François Roman, Thomas Breuer, Piotr Wysocki, Lauren Carter, Sushant Sahastrabuddhe, Manki Song, Naveena D'Cor, Hun Kim, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Hee Jin Cheong, Agathe Philippot, Francesca Solmi, Maria Angeles Ceregido, Byoung-Shik Shim, Sang Hwan Seo, Simone D'Souza, Patchara Thaisrivichai, Josefina Carlos, Edison Alberto, Sorachai Nitayaphan, Winai Ratanasuwan, Piroon Mootsikapun, Romanee Chaiwarith, Luong Chan Quang, Olena Karpenko, Tatiana Yurkiv, Vitalii Kutovyi, Angela Bartko, Olga Gyrina, Olga Barna, Mykhailo Pugach, Claire Thurlow, Simon Carson, Susan Smith, Mike Williams, Tiwini Hemi Senior, Tim Humphrey, Davitt Sheahan, Hokeun Park, Yoon Yeong Lee, Seung Gu Kang

Source: EClinicalMedicine, Vol 64, Iss , Pp 102140- (2023)

Subject Terms: SARS-CoV-2, COVID-19, Recombinant protein vaccine, Nanoparticle vaccine, Immunogenicity, Safety, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2589537023003176; https://doaj.org/toc/2589-5370

Access URL: https://doaj.org/article/608a2ee1e423411eb689bce93946af34

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

Authors: Maria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, Edison Alberto, Deok Ryun Kim, Eun Lyeong Park, Ju Yeon Park, Jae Seung Yang, Jagadeesh Reddy Eluru, Sue-Kyoung Jo, Hun Kim, Seon-Young Yang, Ji Hwa Ryu, Hokeun Park, Jong Hoon Shin, Yoonyeong Lee, Jerome H. Kim, Zenaida Reynoso Mojares, T. Anh Wartel, Sushant Sahastrabuddhe

Source: npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)

Subject Terms: Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2059-0105

Access URL: https://doaj.org/article/e37d05b1c20b4f23851267351eb19f82

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

Authors: Josefina Cadorna Carlos, Birkneh Tilahun Tadesse, Charissa Borja-Tabora, Edison Alberto, Michelle C. Ylade, Arijit Sil, Deok Ryun Kim, Hyeon Seon Ahn, Jae Seung Yang, Ji Yeon Lee, Min Soo Kim, Jiwook Park, Soo-Young Kwon, Hun Kim, Seon-Young Yang, Ji-hwa Ryu, Hokeun Park, Jong-hoon Shin, Yoonyeong Lee, Jerome H. Kim, Zenaida Reynoso Mojares, T. Anh Wartel, Sushant Sahastrabuddhe

Source: The Lancet Regional Health. Western Pacific, Vol 24, Iss , Pp 100484- (2022)

Subject Terms: Typhoid fever, Vi-DT vaccine, Immune equivalence, Single dose formulation, Multidose formulation, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666606522000992; https://doaj.org/toc/2666-6065

Access URL: https://doaj.org/article/c3a9e8c4d0bd42cf8e67b9d30d0b9118